Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29719028 | 1.00 | EGFR (0.41) | EGFRVCAM1TDP1ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL4781507 | 0.98 | EGFR (0.40) | EGFRVCAM1TDP1ATMALDH1A1 | |
| SCHEMBL27768928 | 0.84 | VCAM1 (0.40) | EGFRVCAM1TDP1ATMALDH1A1 | |
| SCHEMBL1469486 | 0.83 | EGFR (0.54) | EGFRVCAM1ALDH1A1ENPP1PDE4A | |
| SCHEMBL30275314 | 0.83 | EGFR (0.54) | EGFRVCAM1ALDH1A1ENPP1PDE4A | |
| SCHEMBL1766092 | 0.83 | ALDH1A1 (0.40) | EGFRVCAM1TDP1ATMALDH1A1 | |
| SCHEMBL30420453 | 0.83 | MAP4K4 (0.43) | EGFRVCAM1TDP1ATMALDH1A1 | |
| SCHEMBL29781306 | 0.83 | ALDH1A1 (0.40) | EGFRVCAM1TDP1ATMALDH1A1 | |
| SCHEMBL17538470 | 0.83 | MAPT (0.40) | EGFRVCAM1TDP1ATMALDH1A1 | |
| SCHEMBL156334 | 0.83 | MAP4K4 (0.43) | EGFRVCAM1TDP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111297865-A | Use of heterocyclic compound-containing composition for preparing medicine for treating lung cancer | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-10550107-B2 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-04 | — | — | US | claimed |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| CN-102702115-A | Synthetic method of 4-chloro-7-fluoro-6-nitro quinazoline | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-03 | — | — | CN | claimed |
| CN-100522965-C | 8-arylamine-3H-imidazole [4,5-g] quinazoline derivatives and its solid phase synthesis method | ZHEJIANG UNIV OF TECHNOLOGY ZH (CN) | 2009-08-05 | — | — | CN | claimed |
| CN-1948314-A | 8-arylamine-3H-imidazole [4,5-g] quinazoline derivatives and its solid phase synthesis method | UNIV ZHEJIANG TECHNOLOGY (CN) | 2007-04-18 | — | — | CN | claimed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260001851-A1 | TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU CONCORD BIOTECHNOLOGY CO LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | JIANGSU CONCORD BIOTECHNOLOGY CO., LTD (CN) | 2025-10-07 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119970743-A | Pharmaceutical use of tyrosine kinase inhibitors | 江苏康可得生物技术股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2000031048-A1 | N-[4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
| CN-1218456-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550107-B2 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | CYP4B1, CYP1B1, CYP2S1 | EGFR 4240/4885VCAM1 4408/4885TDP1 2011/4885 |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | CYP4B1, CYP1B1, CYP2S1 | EGFR 4240/4885VCAM1 4408/4885TDP1 2011/4885 |
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | EGFR 677/4885VCAM1 2831/4885TDP1 951/4885 |
| US-20260001851-A1 | TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL APPLICATION THEREOF | ABL1, ERBB2, ALK | EGFR 7/4885VCAM1 2318/4885TDP1 1787/4885 |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | SRC, ABL1, ERBB2 | EGFR 9/4885VCAM1 4237/4885TDP1 2183/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | EGFR 324/4885VCAM1 2269/4885TDP1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.